BCPC vs EMN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: EMN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCPC and EMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCPC and EMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Balchem Corporation is a specialty ingredients company organized into three segments: Human Nutrition and Health (choline nutrients, encapsulated ingredients, flavor and food systems), Animal Nutrition and Health (microencapsulated feed additives, chelated minerals, and choline chloride for livestock and pets), and Specialty Products (ethylene-oxide sterilization for medical devices, plus fumigants for food safety). It is a leader in choline chemistry and microencapsulation, selling into food, beverage, dietary supplement, animal feed, and healthcare end markets that tend to hold up through economic cycles.

Full BCPC guide

Eastman Chemical Company (NYSE: EMN) is a global specialty materials producer headquartered in Kingsport, Tennessee, organized into four segments: Advanced Materials (specialty films, plastics, and interlayers), Additives and Functional Products (coatings, inks, and performance additives), Chemical Intermediates (commodity and functional chemicals), and Fibers (cellulose acetate tow, largely for cigarette filters). Annual revenue runs around $9 billion, and the company has leaned into circular-economy positioning through its Kingsport methanolysis (molecular recycling) plant, which converts hard-to-recycle plastic waste back into raw materials and added roughly $60 million of incremental earnings in 2025.

Full EMN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCPC drivers: Human Nutrition and Health momentum; Specialty Products and medical sterilization.
• EMN drivers: Molecular recycling ramp; Specialty mix and pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Balchem trades at a premium earnings multiple, so any slowdown in growth or margin pressure could compress the valuation meaningfully. For EMN, eastman is cyclical and sensitive to global industrial demand, energy and raw-material costs, and destocking, all of which pressured 2025 and early 2026 results.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCPC if you believe its drivers more; EMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCPC and EMN guides.

BCPC. Balchem posted record first-quarter 2026 net sales of about $271 million, up roughly 8% year over year, with adjusted EBITDA near $74 million and another quarter of year-over-year adjusted EBITDA growth. Trailing revenue is around $1.06 billion with net income near $158 million. The roughly 34x earnings multiple reflects the market pricing in the company's long consistency rather than any near-term acceleration.

EMN. Eastman trades around $71 per share with a market cap near $8 billion, well below prior highs, reflecting soft recent results and a cyclical backdrop. Q1 2026 sales fell about 5% to ~$2.18 billion and net earnings dropped to ~$107 million, though management guided Q2 adjusted EPS to roughly $1.70 to $1.90. The ~4.5% yield and mid-to-high-teens P/E frame it as a value and income name rather than a growth stock.

Headline figures (approximate, July 2026): BCPC shows revenue (ttm) ~$1.06B, net income (ttm) ~$158M, q1 2026 net sales ~$271M (+8% YoY), q1 2026 adjusted eps ~$1.33; EMN shows revenue (ttm) ~$9.2B, market cap ~$7.9B, p/e ratio ~18.9, fy2025 adjusted eps ~$5.42.

BCPC and EMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCPC and EMN exposure against your real portfolio. It is not an investment adviser.